As of today (2026-07-06), the Forward Annual Dividend Yield of Unipharma Co is 0.00%.
As of today (2026-07-06), the Trailing Annual Dividend Yield of Unipharma Co is 0.00%.
ROCO:6621's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Unipharma Co (ROCO:6621) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Unipharma Co Forward Dividend Yield % Related Terms
ROCO:6621 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Unipharma Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Unipharma Co (ROCO:6621) has a Forward Dividend Yield % of 0.00% as of Jul. 06, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Unipharma Co and its competitors. According to the industry distribution chart, Unipharma Co ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Unipharma Co's Forward Dividend Yield % too high?
Unipharma Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Unipharma Co ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Unipharma Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #999999 out of 507 companies for Forward Dividend Yield %. This places Unipharma Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.63, compared to a current price of NT$11.35 — trading 2.4% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Unipharma Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.35 is trading 2.4% below its estimated GF Value™ of NT$11.63.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
Forward Dividend Yield %: 0.00%
GF Value™: NT$11.63 vs. price of NT$11.35 (2.4% below fair value)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
74GF Score
Get the complete analysis for ROCO:6621
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 